Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson ’s Disease and Dyskinesia
ConclusionThis post hoc analysis shows potential benefit with Gocovri treatment for the NMS of daytime sleepiness and depression in dyskinetic PD patients. Overall, improvement in NMS scores correlated with improvement in dyskinesia.Trial RegistrationClinicalTrials.gov identifiers: NCT02136914 and NCT02274766
Source: Neurology and Therapy - Category: Neurology Source Type: research
More News: Amantadine | Brain | Carbidopa/Levodopa | Constipation | Depression | Dyskinesia | Neurology | Parkinson's Disease | Symmetrel